Is histological prostate inflammation in an initial prostate biopsy a predictor of prostate cancer on repeat biopsy?

PURPOSE - To investigate whether histological inflammation detected in an initial prostate biopsy can predict the risk of prostate cancer on a repeat biopsy.

METHODS - This was a retrospective study of 171 patients who underwent repeat prostate biopsy for persistently elevated prostate-specific antigen after an initial negative biopsy result. The enrolled patients were divided into two groups according to the results of the repeat biopsy: the noncancer group (n = 126) and the cancer group (n = 45). Multivariate regression analysis was used to determine the effect of inflammation grade, aggressiveness, and prostate-related parameters on the detection of prostate cancer at the repeat biopsy.

RESULTS - Prostate inflammation grade (p = 0.005) and aggressiveness (p = 0.001) in the initial biopsy were significantly different between the cancer and noncancer groups. Factors associated with the risk of prostate cancer at the repeat biopsy were age [odds ratio (OR) 1.08; 95 % confidence interval (CI) 1.03-1.14], prostate-specific antigen density (OR 24.30; 95 % CI 9.3-62.9), prostate-specific antigen velocity (OR 1.05; 95 % CI 1.01-1.09), and inflammation aggressiveness (OR 0.05; 95 % CI 0.01-0.27).

CONCLUSIONS - A histological inflammatory finding at the initial prostate biopsy was negatively associated with prostate cancer detection in repeat biopsy. This result could be useful to determine the need for repeat prostate biopsy in patients with persistently elevated prostate-specific antigen.

Int Urol Nephrol. 2015 Aug;47(8):1251-7. doi: 10.1007/s11255-015-1029-6. Epub 2015 Jun 14.

Yun BH1, Hwang EC, Yu HS, Chung H, Kim SO, Jung SI, Kang TW, Kwon DD, Park K, Choi C.

Department of Urology, Chonnam National University Medical School, 42, Jebong-ro, Donggu, Gwangju, 501-757, Republic of Korea.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe